Lana Zhovtis Ryerson

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

Lana Zhovtis Ryerson, John Foley, Ih Chang et al. · Neurology · 2019 · 194 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +16

Extended interval dosing of natalizumab in multiple sclerosis

Lana Zhovtis Ryerson, Teresa C. Frohman, John Foley et al. · Journal of Neurology Neurosurgery & Psychiatry · 2016 · 149 citations

Pharmacy, Neurology, Pharmacotherapy +12

COVID-19 outcomes in MS

Erica Parrotta, Ilya Kister, Leigh Charvet et al. · Neurology Neuroimmunology & Neuroinflammation · 2020 · 148 citations · Full text

Pharmacy, Infectious Diseases, Internal Medicine +8

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson et al. · The Lancet Neurology · 2022 · 110 citations

Medicine, Pharmacology, Pharmacotherapy +11

Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple Sclerosis

Karla Gray-Roncal, Kathryn C. Fitzgerald, Lana Zhovtis Ryerson et al. · Neurology · 2021 · 60 citations · Full text

Medicine, Insurance, Neurology +17